| scholarly article | Q13442814 |
| P50 | author | Stefano Da Sacco | Q82626258 |
| David Warburton | Q30004062 | ||
| P2093 | author name string | Anna Milanesi | |
| Kevin V Lemley | |||
| Laura Perin | |||
| Roger E De Filippo | |||
| Astgik Petrosyan | |||
| Sargis Sedrakyan | |||
| Liron Shiri | |||
| Radka Varimezova | |||
| P2860 | cites work | Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. | Q42495926 |
| Regression of glomerulosclerosis in response to transient treatment with angiotensin II blockers is attenuated by blockade of matrix metalloproteinase-2. | Q43106556 | ||
| Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. | Q45269853 | ||
| In vivo genetic selection of renal proximal tubules. | Q46745497 | ||
| Mesenchymal stem cell injection ameliorates chronic renal failure in a rat model | Q50677532 | ||
| Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. | Q51793488 | ||
| Cellular outgrowth from isolated glomeruli. Origin and characterization. | Q53923579 | ||
| Role of vascular endothelial growth factor in kidney disease. | Q54742928 | ||
| Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury | Q58831554 | ||
| The pathology of the kidney in the Alport syndrome | Q68922610 | ||
| Glycation products in aged thioglycollate medium enhance the elicitation of peritoneal macrophages | Q73111363 | ||
| Characterization of renal interstitial fibroblast-specific protein 1/S100A4-positive cells in healthy and inflamed rodent kidneys | Q81692025 | ||
| Macrophages and Dendritic Cells for Treating Kidney Disease | Q84977090 | ||
| Protective effect of human amniotic fluid stem cells in an immunodeficient mouse model of acute tubular necrosis | Q21142646 | ||
| Stem cells derived from human amniotic fluid contribute to acute kidney injury recovery | Q24598466 | ||
| Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease | Q25256594 | ||
| Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis | Q28257040 | ||
| The chemokine system in diverse forms of macrophage activation and polarization | Q29547719 | ||
| The many faces of macrophage activation | Q29617449 | ||
| Mesenchymal stem cells reside in virtually all post-natal organs and tissues | Q29617740 | ||
| Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats | Q31063566 | ||
| Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans | Q33556295 | ||
| Stem cell therapies benefit Alport syndrome | Q33561731 | ||
| Renal pathology and ultrastructural findings in Alport's syndrome | Q34097243 | ||
| Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans | Q34245363 | ||
| Isolation of amniotic stem cell lines with potential for therapy | Q34598404 | ||
| Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease | Q34624477 | ||
| Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages | Q35215695 | ||
| Pathophysiology of acute kidney injury: roles of potential inhibitors of inflammation | Q36803519 | ||
| Irradiation prolongs survival of Alport mice | Q36842383 | ||
| Macrophage diversity in renal injury and repair. | Q36955562 | ||
| Mesenchymal stem cells in acute kidney injury | Q36960106 | ||
| Interleukin-23 and TH17 cells in transplantation immunity: does 23+17 equal rejection? | Q36999663 | ||
| Stem cell and regenerative science applications in the development of bioengineering of renal tissue | Q37143890 | ||
| Stem cell therapy for Alport syndrome: the hope beyond the hype | Q37463203 | ||
| Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists | Q37764890 | ||
| Glomerular basement membrane composition and the filtration barrier | Q37843806 | ||
| Human amniotic fluid as a potential new source of organ specific precursor cells for future regenerative medicine applications. | Q38452430 | ||
| An image analysis-based method for quantification of chronic allograft damage index parameters | Q39762982 | ||
| Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor. | Q40873757 | ||
| Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. | Q41575948 | ||
| A new method for large scale isolation of kidney glomeruli from mice | Q42047954 | ||
| Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome | Q42048146 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 661-673 | |
| P577 | publication date | 2012-02-02 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Injection of amniotic fluid stem cells delays progression of renal fibrosis | |
| P478 | volume | 23 |
| Q27300847 | A novel source of cultured podocytes |
| Q39439987 | A step towards clinical application of acellular matrix: A clue from macrophage polarization. |
| Q52718217 | Alport syndrome and Pierson syndrome: Diseases of the glomerular basement membrane. |
| Q38244117 | Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies |
| Q38061008 | Alport syndrome--insights from basic and clinical research |
| Q39377520 | Amniotic fluid cells: current progress and emerging challenges in renal regeneration. |
| Q46203329 | Amniotic fluid stem cell-derived vesicles protect from VEGF-induced endothelial damage |
| Q91695695 | Amniotic fluid stem cells ameliorate cisplatin-induced acute renal failure through induction of autophagy and inhibition of apoptosis |
| Q34964361 | Amniotic fluid stem cells inhibit the progression of bleomycin-induced pulmonary fibrosis via CCL2 modulation in bronchoalveolar lavage |
| Q42688945 | Amniotic fluid stem cells prevent β-cell injury |
| Q33816234 | Amniotic fluid-derived mesenchymal stem cells prevent fibrosis and preserve renal function in a preclinical porcine model of kidney transplantation. |
| Q46049280 | Amniotic therapeutic biomaterials in urology: current and future applications |
| Q38035773 | An update on the pathomechanisms and future therapies of Alport syndrome |
| Q92459933 | Basement membrane collagens and disease mechanisms |
| Q38049499 | CD117(+) amniotic fluid stem cells: state of the art and future perspectives |
| Q38528934 | Cell-based therapy for kidney disease |
| Q38941236 | Collagen IV diseases: A focus on the glomerular basement membrane in Alport syndrome |
| Q39051358 | Concise Review: Amniotic Fluid Stem Cells: The Known, the Unknown, and Potential Regenerative Medicine Applications |
| Q57292611 | Concise Reviews: Stem Cells and Kidney Regeneration: An Update |
| Q42247713 | Direct Isolation and Characterization of Human Nephron Progenitors |
| Q58575060 | Endoplasmic reticulum stress response is activated in pulmonary hypoplasia secondary to congenital diaphragmatic hernia, but is decreased by administration of amniotic fluid stem cells |
| Q28084505 | Engineering muscle tissue for the fetus: getting ready for a strong life |
| Q39188571 | Engineering tissue for the fetus: stem cells and matrix signalling |
| Q37670342 | Feasibility of repairing glomerular basement membrane defects in Alport syndrome |
| Q97530054 | Glomerular endothelial cell heterogeneity in Alport syndrome |
| Q90141942 | Human amniotic fluid stem cells have a unique potential to accelerate cutaneous wound healing with reduced fibrotic scarring like a fetus |
| Q34751229 | Immune regulatory properties of CD117(pos) amniotic fluid stem cells vary according to gestational age |
| Q38424646 | Kidney diseases and tissue engineering |
| Q38658621 | Kidney transplantation, bioengineering and regeneration: an originally immunology-based discipline destined to transition towards ad hoc organ manufacturing and repair. |
| Q57041776 | Kidney-derived c-kit progenitor/stem cells contribute to podocyte recovery in a model of acute proteinuria |
| Q61818598 | Mesenchymal Stem Cells in Renal Fibrosis: The Flame of Cytotherapy |
| Q92597668 | Progenitor/Stem Cell Delivery by Suprarenal Aorta Route in Acute Kidney Injury |
| Q38339791 | Prospect for kidney bioengineering: shortcomings of the status quo. |
| Q46266188 | Protective effect of GDNF-engineered amniotic fluid-derived stem cells on the renal ischaemia reperfusion injury in vitro |
| Q50042214 | Recent Updates on Treatment of Ocular Microbial Infections by Stem Cell Therapy: A Review |
| Q38674374 | Regenerating a kidney in a lymph node. |
| Q26865171 | Regenerative medicine for the kidney: renotropic factors, renal stem/progenitor cells, and stem cell therapy |
| Q45871465 | Renal, auricular, and ocular outcomes of Alport syndrome and their current management |
| Q34453272 | Searching for a treatment for Alport syndrome using mouse models |
| Q38544667 | Stem cell therapy for kidney disease. |
| Q42924514 | The 2014 International Workshop on Alport Syndrome. |
| Q27004398 | The Regenerative Role of the Fetal and Adult Stem Cell Secretome |
| Q35859120 | The Role of M2 Macrophages in the Progression of Chronic Kidney Disease following Acute Kidney Injury |
| Q45356197 | The effect of meconium exposure on the expression and differentiation of amniotic fluid mesenchymal stem cells |
| Q91681008 | The importance of clinician, patient and researcher collaborations in Alport syndrome |
| Q52563089 | The presence of human mesenchymal stem cells of renal origin in amniotic fluid increases with gestational time. |
| Q39211384 | The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases |
Search more.